S. Shaver

发表

Structure–activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors

J. Boyer, M. Picher, W. Pendergast, 2005, Purinergic Signalling.

P2Y receptors: biological advances and therapeutic opportunities.

S. R. Shaver, S. Shaver, 2001, Current opinion in drug discovery & development.

2-amino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl)-6-substituted-9H-purines: synthesis and anti-HIV activity.

S. Short, G. A. Freeman, J. L. Rideout, 1995, Bioorganic & medicinal chemistry.

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.

E. Garvey, C. M. Yates, R. Schotzinger, 2017, Bioorganic & medicinal chemistry letters.

4-Substituted Uridine 5′-Triphosphates as Agonists of the P2Y2 Purinergic Receptor

M. K. James, S. Siddiqi, W. Pendergast, 1997 .

Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.

I. Sims, W. Pendergast, J. Douglass, 2001, Bioorganic & medicinal chemistry letters.

Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor.

J. Boyer, J. Douglass, C. Redick, 2008, Journal of medicinal chemistry.

Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation.

R. Tidwell, J. Geratz, S. R. Shaver, 1981, Thrombosis research.

Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors.

R. Tidwell, J. Geratz, W. P. Webster, 1980, Thrombosis research.